Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4'-ethynyl-2'-deoxycytidine
- Development stage
- Preclinical
- Lead developer
- Thomas Jefferson University
- Modality
- Small Molecules
- Administration
- Intraperitoneal, Oral
01
Overview
4'-Ethynyl-2'-deoxycytidine (EdC) is a preclinical, small-molecule nucleoside analog and prodrug being investigated for the treatment of hematologic malignancies, specifically diffuse large B-cell lymphoma (DLBCL) and acute lymphoblastic leukemia (ALL). EdC requires intracellular phosphorylation by deoxycytidine kinase (DCK) to its active triphosphate form, which then acts as a DNA chain terminator, inducing replication fork arrest, replicative stress, and S-phase cell cycle accumulation. EdC is designed to resist cytidine deamination and SAMHD1-mediated degradation, overcoming common nucleoside analog resistance mechanisms. It has demonstrated high potency and in vivo efficacy against DLBCL and ALL models.
- Other names
- 2'-deoxy-4'-C-ethynylcytidine2'-deoxy-4'-ethynylcytidine4'-C-ethynyl-2'-deoxycytidine4′-ethynyl-2′-deoxycytidineEdC
02
Targets
DNADCK (Deoxycytidine kinase)
Beyond the preview
Go deeper on 4'-ethynyl-2'-deoxycytidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4'-ethynyl-2'-deoxycytidine.